Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.61 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242266 | 0.91 | CNR1 (0.73) | CNR1MALT1NR1H4PTGES | |
| SCHEMBL4248267 | 0.73 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL4253970 | 0.72 | CNR1 (0.45) | CNR1MALT1CNR2 | |
| SCHEMBL4243036 | 0.71 | CNR1 (0.48) | CNR1FFAR1FFAR4 | |
| SCHEMBL4679409 | 0.70 | CNR1 (1.00) | CNR1NR1H4PTGES | |
| SCHEMBL4243035 | 0.69 | CNR1 (0.48) | CNR1FFAR1FFAR4 | |
| SCHEMBL4599786 | 0.68 | CNR1 (0.47) | CNR1FFAR1FFAR4 | |
| SCHEMBL4614699 | 0.65 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL4600547 | 0.64 | CNR1 (0.69) | CNR1MALT1NR1H4 | |
| SCHEMBL4614174 | 0.64 | CNR1 (0.64) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | claimed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| CN-101282937-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR1 173/4885MALT1 3573/4885NR1H4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.